​​​
  1. Nomura upgrades Lupin to ‘Buy’ from ‘Neutral’, shares up

Nomura upgrades Lupin to ‘Buy’ from ‘Neutral’, shares up

Japanese brokerage firm Nomura has upgraded the stocks of Lupin to 'Buy' from 'Neutral' citing the high impact drug approvals that will drive company's earnings from Q4 onwards.

By: | Updated: September 22, 2015 4:14 PM
Lupin shares-Nomura

Japanese brokerage firm Nomura has upgraded the stocks of Lupin to ‘Buy’ from ‘Neutral’ citing the high impact drug approvals that will drive company’s earnings from Q4 onwards. (Reuters)

Japanese brokerage firm Nomura has upgraded the stocks of Lupin to ‘Buy’ from ‘Neutral’ citing the high impact drug approvals will drive company’s earnings from Q4 onwards.

The brokerage firm raised Lupin target price to Rs 2,149 per share from Rs 1,698 earlier.

At 10.49 am, Lupin was trading 0.33 per cent up at Rs 1,887.50 on BSE.

Nomura added further that generic version of Glumetza, Nexium, Welchol and Renvela/Renagel will matter most for growth.

HSBC had also upgraded the stock to “buy” from “hold” last week.

Lupin stock has 23 buy, 14 hold and 6 sell ratings, according to Eikon data.

Later, the Lupin shares wiped off day’s gains and closed 0.68 per cent down at Rs 1,868.48 apiece.

With Reuters inputs

Get live Stock Prices from BSE and NSE and latest NAV, portfolio of Mutual Funds, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Tags: LupinNomura

Go to Top